Last reviewed · How we verify
Levetiracetam Pill
At a glance
| Generic name | Levetiracetam Pill |
|---|---|
| Also known as | Keppra |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- R33: Levetiracetam in Early Psychosis (PHASE2)
- Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia (PHASE1, PHASE2)
- Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults (PHASE2)
- Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia (NA)
- Pharmacological Modulation of Hippocampal Activity in Psychosis 2 (PHASE2)
- Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism (PHASE2)
- Levetiracetam XR in Very Heavy Drinkers (PHASE2)
- Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levetiracetam Pill CI brief — competitive landscape report
- Levetiracetam Pill updates RSS · CI watch RSS
- NYU Langone Health portfolio CI